# Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

> **NCT06826872** · PHASE2 · RECRUITING · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 252 (estimated)

## Conditions studied

- Hypertension, Essential
- Cardiovascular Diseases
- Cardiology

## Interventions

- **DRUG:** SPC 1001 Mid2
- **DRUG:** SPC 2002
- **DRUG:** SPC 2003
- **DRUG:** SPC 2004

## Key facts

- **NCT ID:** NCT06826872
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2025-10-08
- **Final completion:** 2025-12-30
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826872, "Efficacy and Safety of SPC1001 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06826872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*